A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John C. Davis, Jr., M.D., M.P.H.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
67 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Sofia, Bulgaria
- Facility name not stated
Sofia, Bulgaria
- Facility name not stated
Sofia, Bulgaria
- Facility name not stated
Santiago, Chile
- Facility name not stated
Santiago, Chile
- Facility name not stated
Santiago, Chile
- Facility name not stated
Bad Nauheim, Germany
- Facility name not stated
Berlin, Germany
- Facility name not stated
Cologne, Germany
- Facility name not stated
Erfurt, Germany
- Facility name not stated
Freiburg im Breisgau, Germany
- Facility name not stated
Herne, Germany
- Facility name not stated
Kiel, Germany
- Facility name not stated
Zerbst, Germany
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Békéscsaba, Hungary
- Facility name not stated
Debrecen, Hungary
- Facility name not stated
Veszprém, Hungary
- Facility name not stated
Culiacán, Mexico
- Facility name not stated
Guadalajara, Mexico
- Facility name not stated
Guadalajara, Mexico
- Facility name not stated
Guadalajara, Mexico
- Facility name not stated
León, Mexico
- Facility name not stated
Mexicali, Mexico
- Facility name not stated
Mexico City, Mexico
- Facility name not stated
Monterrey, NL, Mexico
- Facility name not stated
Mérida, Mexico
- Facility name not stated
México, Mexico
- Facility name not stated
Lima, Peru
- Facility name not stated
Lima, Peru
- Facility name not stated
Lima, Peru
- Facility name not stated
Lima, Peru
- Facility name not stated
Lima, Peru
- Facility name not stated
Lima, Peru
- Facility name not stated
San Isidro, Peru
- Facility name not stated
San Isidro, Peru
- Facility name not stated
Bialystok, Poland
- Facility name not stated
Bialystok, Poland
- Facility name not stated
Elblag, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2010
- Primary completion
- 31 Jul 2012
- Completion
- —
- Last update posted
- 2 Nov 2016
- Registered enrollment
- 211
- Registry id
- NCT01225393
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.